559 related articles for article (PubMed ID: 25125481)
1. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.
Lapa C; Linsenmann T; Monoranu CM; Samnick S; Buck AK; Bluemel C; Czernin J; Kessler AF; Homola GA; Ernestus RI; Löhr M; Herrmann K
J Nucl Med; 2014 Oct; 55(10):1611-6. PubMed ID: 25125481
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
[TBL] [Abstract][Full Text] [Related]
3. Comparison Between 18F-Dopa and 18F-Fet PET/CT in Patients with Suspicious Recurrent High Grade Glioma: A Literature Review and Our Experience.
Evangelista L; Cuppari L; Bellu L; Bertin D; Caccese M; Reccia P; Zagonel V; Lombardi G
Curr Radiopharm; 2019; 12(3):220-228. PubMed ID: 30644351
[TBL] [Abstract][Full Text] [Related]
4. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
5. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.
Pafundi DH; Laack NN; Youland RS; Parney IF; Lowe VJ; Giannini C; Kemp BJ; Grams MP; Morris JM; Hoover JM; Hu LS; Sarkaria JN; Brinkmann DH
Neuro Oncol; 2013 Aug; 15(8):1058-67. PubMed ID: 23460322
[TBL] [Abstract][Full Text] [Related]
6. Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors.
Kratochwil C; Combs SE; Leotta K; Afshar-Oromieh A; Rieken S; Debus J; Haberkorn U; Giesel FL
Neuro Oncol; 2014 Mar; 16(3):434-40. PubMed ID: 24305717
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
Bashir A; Brennum J; Broholm H; Law I
J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
[TBL] [Abstract][Full Text] [Related]
8. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
9. Preferred transport of O-(2-[18F]fluoroethyl)-D-tyrosine (D-FET) into the porcine brain.
Makrides V; Bauer R; Weber W; Wester HJ; Fischer S; Hinz R; Huggel K; Opfermann T; Herzau M; Ganapathy V; Verrey F; Brust P
Brain Res; 2007 May; 1147():25-33. PubMed ID: 17343835
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ
J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243
[TBL] [Abstract][Full Text] [Related]
11. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.
Galldiks N; Stoffels G; Filss CP; Piroth MD; Sabel M; Ruge MI; Herzog H; Shah NJ; Fink GR; Coenen HH; Langen KJ
J Nucl Med; 2012 Sep; 53(9):1367-74. PubMed ID: 22872742
[TBL] [Abstract][Full Text] [Related]
12. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors.
Pauleit D; Floeth F; Tellmann L; Hamacher K; Hautzel H; Müller HW; Coenen HH; Langen KJ
J Nucl Med; 2004 Mar; 45(3):374-81. PubMed ID: 15001676
[TBL] [Abstract][Full Text] [Related]
13. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
[TBL] [Abstract][Full Text] [Related]
14. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
[TBL] [Abstract][Full Text] [Related]
15. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.
Pyka T; Gempt J; Hiob D; Ringel F; Schlegel J; Bette S; Wester HJ; Meyer B; Förster S
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):133-141. PubMed ID: 26219871
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
17. Treatment-Related Uptake of
Geisler S; Stegmayr C; Niemitz N; Lohmann P; Rapp M; Stoffels G; Willuweit A; Galldiks N; Filss C; Sabel MC; Coenen HH; Shah NJ; Langen KJ
J Nucl Med; 2019 Oct; 60(10):1373-1379. PubMed ID: 30850492
[TBL] [Abstract][Full Text] [Related]
18. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy.
Calcagni ML; Galli G; Giordano A; Taralli S; Anile C; Niesen A; Baum RP
Clin Nucl Med; 2011 Oct; 36(10):841-7. PubMed ID: 21892031
[TBL] [Abstract][Full Text] [Related]
19. Comparison of
Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
[TBL] [Abstract][Full Text] [Related]
20. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
